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Pasteurella multocida is the causative agent of fowl cholera in birds. Signature-tagged mutagenesis (STM) was
used to identify potential virulence factors in a mouse septicemia disease model and a chicken fowl cholera
model. A library of P. multocida mutants was constructed with a modified Tn916 and screened for attenuation
in both animal models. Mutants identified by the STM screening were confirmed as attenuated by competitive
growth assays in both chickens and mice. Of the 15 mutants identified in the chicken model, only 5 were also
attenuated in mice, showing for the first time the presence of host-specific virulence factors and indicating the
importance of screening for attenuation in the natural host.
Pasteurella multocida is a capsulated, gram-negative cocco-
bacillus and is the causative agent of avian fowl cholera, bovine
hemorrhagic septicemia, atrophic rhinitis in pigs, and snuffles
in rabbits (30). To date, few virulence factors of P. multocida
have been identified; they include the capsule in serogroups A
and B (7, 10), PMT toxin in strains causing atrophic rhinitis
(16), putative filamentous hemagglutinins PfhB1 and PfhB2
(17), and several iron acquisition proteins, such as TonB,
ExbD, and ExbB (6, 17, 31).
Recently, several studies have been undertaken to identify
the genes involved in the pathogenesis of pasteurellosis, in-
cluding in vivo expression technology (22), signature-tagged
mutagenesis (STM) (17), and whole-genome expression pro-
filing (8). These genomic-scale methods have identified some
true virulence factors and virulence-associated genes, including
those involved in iron transport and metabolism as well as
nucleotide and amino acid biosynthesis. However, many genes
identified by these analyses have no known function, and nei-
ther in vivo expression technology nor whole-genome expres-
sion profiling gives direct information about the importance of
genes in virulence.
STM allows the large-scale screening of mutants for reduced
survival in vivo, colonization and adhesion defects, and de-
creased invasive ability (3, 9, 20). The method has been applied
to many bacterial species, including a previous study on a
bovine isolate of P. multocida using a tagged mini-Tn10 (17).
This previous study used a septicemic mouse model of infec-
tion and identified 25 P. multocida genes that were important
for survival and growth in vivo. However, one-third of the 62
mutants identified in that study contained multiple transposon
insertions, and in these instances, it was not possible to deter-
mine the gene responsible for the attenuated phenotype (17).
In this study, we report the screening of an STM bank of
P. multocida mutants in two animal models to identify, for the
first time, potential host-specific virulence factors. We screened
the mutant library in mice, the most widely used P. multocida
animal model, and in chickens, the natural host.
Modification of Tn916 for use in STM of P. multocida. The
transposon Tn916 has been shown to transpose in a quasiran-
dom fashion into the P. multocida genome (14). In addition,
tetracycline resistance was stable in the absence of selection
over many generations, and the transposon could be intro-
duced into P. multocida by electroporation rather than conju-
gation, avoiding the need for a recipient strain carrying a coun-
terselectable marker (14). However, in our study, the inherent
instability of the transposon in the base plasmid pAM120 (18)
resulted in an inadequate number of tagged transposons being
generated for library construction. To overcome this problem,
we constructed a smaller version of the transposon, designated
Tn916EC, that was stable for manipulation in Escherichia coli
and, when required, could be restored to an active transposon
by removal of the erm(B) cassette from the int gene (Fig. 1).
Briefly, two PCR products were generated from pAM120.
The first was generated with primers BAP1127 (AGCAGTTC
TAGATGATGATACTGTCCC) and BAP1126 (TCGCTGCT
CGAGTTTATCCTCGCCAG) and included the right and left
junctions of the transposon, the 3 end of the int gene, and the
entire base plasmid (Fig. 1). An XhoI site and XbaI site were
introduced near the right junction of the transposon and the 3
end of the int gene, respectively. The second fragment, ampli-
fied with BAP1128 (TCATCATCTAGAACTGCTTTCAG
TTG) and BAP1129 (TTTGGTACTCGAGAAGAACGGG
AG), included the 5 end of the int gene (and an XbaI site) and
the entire tetracycline resistance gene, tet(M). An XhoI site
was also generated at the end of this fragment upstream of the
tet(M) gene. A third fragment of DNA containing an erm(B)
gene conferring erythromycin resistance was purified after di-
gestion of the plasmid pJIR599 (4) with XbaI and inserted into
the XbaI site engineered within the int gene. All three frag-
ments were then ligated, and the subsequent E. coli transfor-
mants were screened for the correct plasmid profile. The
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erm(B) insertion resulted in the inactivation of transposon
excision during DNA manipulations, and the XbaI site located
at either end of the erm(B) gene allowed the removal of the
cassette when transposition was required. The modified trans-
poson was designated Tn916EC, as it conferred erythromycin
resistance (E) and no longer contained the conjugation genes
(C). Tn916EC in pAM120 was designated pPBA1638, which
is a suicide vector in P. multocida. Prior to transposition into
P. multocida, the erm(B)cassette was removed by enzyme di-
gestion and religation. Tn916EC was shown to transpose in a
quasirandom fashion in P. multocida, and most mutants had
only a single transposon insertion (data not shown).
Construction and cloning of DNA tags. The variable oligo-
nucleotide used for construction of the tagged Tn916EC was
essentially as described previously (20). To ensure tag fidelity,
we constructed the tag from three oligonucleotides (Fig. 2)
The first, designated BAP1298 [GTACAACCTCAAGCTT
(NK)20GAATTCGGTTAGAATG], was a 72-bp oligonucleo-
tide, which included the 40-bp variable region. The remaining
bases required for cloning into Tn916EC were synthesized on
separate oligonucleotides BAP1299 (ATAAACCCGGGTAC
AACCTCAAGCT) and BAP1300 (GCATCCCGGGCATTC
TAACCGAATTC), and each included an XmaI site for inser-
tion into the BspEI site of Tn916. Double-stranded tags were
generated by annealing BAP1298 and BAP1300 and allowing
T4 polymerase to fill the 5 single-stranded extensions. The
resulting double-stranded molecule was further extended by
PCR amplification using oligonucleotides BAP1299 and
BAP1300 (Fig. 2).
Generation of a P. multocida signature-tagged Tn916EC
library. For construction of the tagged transposon library, the
plasmid pPBA1638 was digested with BspE1 (Fig. 1) and li-
gated to XmaI-digested DNA tags, generating a plasmid which
could no longer be digested by either enzyme. Prior to elec-
troporation into competent E. coli DH5 cells, the ligated
products were digested with BspEI to digest any plasmid not
containing a DNA tag.
A library of 42 uniquely tagged Tn916EC transposons in
the plasmid pPBA1638 was constructed by selecting tagged
transposons that would act as efficient templates for PCR and
hybridize specifically in DNA dot blot hybridizations. Prior to
transposition into P. multocida, the erm(B) cassette was re-
moved from the plasmids by digestion with XbaI and self-
ligation. Each plasmid harboring a uniquely tagged transposon
was then introduced separately into P. multocida strain VP161
by electroporation. Mutant pools, each containing 42 mutants,
FIG. 1. Schematic representation of the strategy used to construct Tn916EC. (A) Linear diagram of pAM120. Bold lines represent the
transposon Tn916, and the fine line represents the base plasmid. Only genes of relevance are shown. Arrows above the line indicate the direction
of amplification from each oligonucleotide (not to scale). tet(M), tetracycline resistance gene; int, integrase gene required for excision and
integration of the transposon; RJ, right junction of the transposon; LJ, left junction. (B) Fragments generated for construction of Tn916EC. The
erythromycin gene [erm(B)] was obtained by digestion of the plasmid pJIR599 with XbaI. The remaining fragments and the restriction sites XhoI
and XbaI were generated by PCR amplification of pAM120 with the oligonucleotides shown in panel A. (C) Diagrammatic representation of the
plasmid pPBA1638 containing the transposon Tn916EC. The vertical arrow labeled TAG indicates the site of insertion (BspE1) of the variable
DNA tags.
FIG. 2. Construction of the variable DNA tags. The figure is not
drawn to scale. The oligonucleotide BAP1298, consisting of 72 bp,
including the 40-bp variable region, was used as a template for the
full-length tag construction. Double-stranded tags were generated by
annealing the oligonucleotides BAP1298 and BAP1300 and allowing
T4 polymerase to fill the 5 single-stranded extensions. The resulting
double-stranded molecule was further extended by PCR amplification
with oligonucleotides BAP1299 and BAP1300.
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were assembled by selecting a single P. multocida colony from
each transformation plate, and the procedure was repeated
until 10 pools were assembled.
Other studies have indicated that the animal model chosen
for STM studies can influence the genes identified, as some
virulence genes will be host specific or involved in host adap-
tation (47). We therefore chose to use two animal models,
namely, the mouse, which has been used regularly as a model
for fowl cholera, and the chicken, a natural host for P. multo-
cida.
Screening of the P. multocida mutant library in vivo. For
each input pool, the mutants were grown separately overnight,
and an aliquot from each culture was transferred to a fresh
tube. A sample of the mix was then spread onto brain heart
infusion (BHI) plates with tetracycline and grown overnight.
Colonies were washed from the plate and used to prepare
genomic DNA representing the input pool.
For screening in mice, female, inbred BALB/c mice, aged 8
to 10 weeks, were injected intraperitoneally with approxi-
mately 105 CFU (approximately 2  102 CFU/mutant) from
the input pool to ensure that all mutants were well repre-
sented. This dose gave reproducible disease progression, and
all mice showed terminal signs of disease within 6 h, when
blood was recovered and the animals were euthanized in ac-
cordance with animal ethics requirements. After infection,
blood was diluted fivefold in BHI and spread onto BHI plates
containing tetracycline. A minimum of 5,000 colonies were
washed from these plates and used to prepare genomic DNA
representing the output pool.
Each pool of mutants was tested in two mice, and the rela-
tive abundance of each tag in the input and output pools was
determined by dot blot hybridization. Genomic DNA from
bacteria isolated from both animals was pooled prior to gen-
eration of the output probe and therefore represented the
average output profile from two animals.
For preparation of the labeled probe, genomic DNA iso-
lated from each pool was used as a template for PCR ampli-
fication with the primers BAP1129 and BAP1414 (GTGCAT
GAAATAATATACGAGT), generating an 800-bp fragment
that contained the unique tag region. The amplified products
were digested with HindIII and EcoRI (located at the end of
the variable tag region) followed by Klenow end filling. The
digested DNA was then separated on a 20% polyacrylamide
gel, eluted overnight (2), and then labeled with the digoxigenin
oligonucleotide 3 end labeling kit (Roche Diagnostics). For
preparation of the target DNA for high-stringency dot blot
hybridizations, each tag was amplified separately by PCR with
the primers BAP1414 and BAP1129, and 1 ng of amplified
product was spotted onto nylon filters.
Mutants were identified as displaying reduced growth in vivo
if the hybridization with the corresponding target DNA was
stronger with the input probe than with the output probe.
Mutants identified in the first screening were collected into a
new pool, injected into a mouse, and used in a second STM
screen. After the second STM screening, 15 mutants were
identified that were potentially attenuated. Each mutant was
then tested in a competitive growth assay together with wild-
type strain VP161.
For screening of each STM pool in chickens, duplicate
chickens (commercially obtained Leghorn cross) were infected
by injection of approximately 105 CFU of the pool into the
breast muscle. Infections were allowed to proceed until the
onset of terminal signs of infection (12 to 16 h), whereupon
blood was recovered and the birds were euthanized in accor-
dance with animal ethics requirements. An output probe was
generated from the bacteria recovered from each bird and
used separately in dot blot hybridizations to determine the
relative abundance of each tagged mutant.
Thirty-five mutants were identified as having reduced output
hybridization signals and subsequently tested individually for
reduced growth in vivo with competitive growth assays.
Identification of attenuated strains in both animal hosts.
Competitive growth assays were used to quantify the relative
growth rates of putative attenuated mutants. Log-phase cul-
tures of mutant and wild-type were mixed at a ratio of 1:1, and
serial 10-fold dilutions were prepared. To determine the input
ratio of wild-type to mutant organisms, 100 l of the appro-
priately diluted culture was plated immediately onto NB agar
in order to obtain single colonies representing the input pool.
For the in vivo growth assays, animals were infected with ap-
proximately 105 CFU, and blood samples were obtained at the
terminal stages of the disease (6 h for mice or 12 to 18 h for
chickens). Blood was diluted twofold in BHI containing hep-
arin and plated onto NB agar. For the in vitro growth assay, a
100-fold dilution of the mixed bacteria was grown in BHI at
37°C with shaking for the same length of time as the animal
infections, diluted appropriately, and spread onto NB agar.
After growth on nonselective plates, a minimum of 100 in-
dividual colonies was patched onto NB agar with or without
tetracycline. Mutants were identified as attenuated if the pro-
portion of mutants obtained after in vivo growth was signifi-
cantly less than the proportion obtained after in vitro growth.
Significance was determined by calculating the P value by an
approximate z test for the difference in two proportions (Table
1) The relative competitive index (rCI) was determined by
dividing the percentage of tetracycline-resistant colonies
(transposon mutants) obtained in vivo by the percentage of
tetracycline-resistant colonies obtained in vitro (Table 1).
Of the 15 mutants originally identified in mice, only 5 were
significantly attenuated, as determined by the competitive
growth assay in mice (Table 1). Subsequent competitive growth
assays in chickens showed that all five mutants were also at-
tenuated in chickens, although the level of attenuation varied
between the two hosts.
Fifteen of the 35 mutants identified in the STM screening in
chickens showed significantly reduced growth in competitive
growth assays in chickens. Each of these was also tested in
competitive growth assays in mice to assess whether there was
a difference in the level of attenuation between the two animal
models (Table 1). Only 5 of the 15 mutants were also attenu-
ated in mice; these were the same mutants identified in the
mouse STM screening.
Southern hybridization confirmed single transposon inser-
tions in all mutants. To identify the exact site of transposon
insertion, inverse PCR was performed using Sau3A-digested
and ligated genomic DNA as the template and oligonucleo-
tides BAP1128 and BAP2252 (ACATAGAATAAGGCTTTA
CGAGC) (36). The amplified products were sequenced di-
rectly by using BAP2252, and P. multocida DNA sequence
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adjoining the Tn916 sequence was searched against the Gen-
Bank database with the BLASTX algorithm (1).
Attenuated strains with insertions in metabolic genes. We
identified a number of mutants that had transposon insertions
affecting genes encoding biosynthetic enzymes, including purN,
pyrF, and deoC. Previous global screenings in bacteria such as
Staphylococcus aureus, Streptococcus pneumoniae, and Yersinia
enterocolitica also identified many biosynthetic genes which
were important for growth in vivo (11, 13, 26). The mutant
AL252 had an insertion in the purN gene and was attenuated
TABLE 1. Characterization of the P. multocida mutants
Group and mutant Disrupted gene or region Predicted function or homologue
Competitive growth assay results in:
Mouse Chicken
rCIa P valueb rCIa P valueb
Attenuated in chickens and mice
AL249 dcaA Phosphoethanolamine transferase 0.33 0.01 0.34 0.01
0.41 0.01 0.66 0.01
0.12 0.01 0.35 0.01
AL250 pm0855 (flp1) Surface adhesion 0.62 0.01 0.39 0.01
0.67 0.01 0.49 0.01
0.50 0.01 0.89 0.18
0.79 0.02
0.71 0.01
AL251 pm1294 Heptosyl transferase 0.62 0.01 0.01 0.01
0.44 0.01 0.01 0.01
0.77 0.03 0.01 0.01
0.64 0.01
AL252 purN De novo purine biosynthesis 0.20 0.01 0.41 0.01
0.16 0.01 0.83 0.15
0.40 0.01 0.28 0.01
0.39 0.01
AL396 Upstream of pm0529 Sodium/alanine symport protein 0.42 0.01 0.16 0.01
0.13 0.01
0.20 0.01
Attenuated only in chickens
AL383 Between rpl20 and pm0606 Unknown 1.13 0.90 0.65 0.01
AL386 pm1069 Homology with H. influenzae P1
surface protein
0.86 0.15 0.26 0.01
1.29 0.89
AL387 deoC Deoxyribose synthesis 1.02 0.56 0.69 0.01
AL388 pyrF Pyrimidine biosynthesis 1.48 0.99 0.58 0.01
0.90 0.19
AL389 ponC Penicillin binding, murein synthesis 0.97 0.44 0.57 0.01
AL390 pm1294 Heptosyl transferase; transposon in
opposite orientation to AL251
0.72 0.04 0.47 0.01
0.83 0.15
1.13 0.20
AL391 pm1294 Heptosyl transferase; transposon in
same orientation as AL251
0.85 0.08 0.01 0.01
1.08 0.69 0.04 0.01
1.07 0.24
AL392 pm0081 Homology with HI0902; probable
integral membrane protein
1.18 0.84 0.42 0.01
AL393 Between purD and glyA Probable effect on glyA, which encodes
glycine hydroxymethyltransferase
1.00 0.50 0.73 0.01
AL407 295 bp upstream of tfoX Between tfoX and a 16S RNA gene 3.15 0.99 0.33 0.01
a Values represent the rCI calculated for individual animals, determined by dividing the in vivo competitive index (CI) by the in vitro CI. Each CI value was
determined by dividing the output mutant/wild-type ratio by the input mutant/wild-type ratio.
b P values were calculated by using an approximate z test for the difference in two proportions. The test was performed to determine if the proportion of mutants
in vivo was significantly less than the proportion obtained in vitro.
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in both mice and chickens (Table 1). This gene encodes the
enzyme 5-phosphoribosylglycinamide transformalase N, which
catalyzes the fourth step of de novo purine biosynthesis (48).
The ability to synthesize purine nucleotides from simple pre-
cursors has been identified as being important for bacterial
growth in vivo, and it has been reported recently that several of
the genes involved in purine biosynthesis in P. multocida are
up-regulated in bacteria harvested from the blood of infected
chickens (8). In addition, in a previous STM study on a bovine
isolate of P. multocida in mice, a purF mutant was identified,
the product of which is also involved in the de novo purine
biosynthesis pathway (17). The mutant AL388 (Table 1) was
attenuated only in chickens and had an insertion in the pyrF
gene, which encodes an orotidine 5-monophosphate decar-
boxylase that in E. coli is involved in pyrimidine biosynthesis
(34).
The mutant AL387 had an insertion upstream of deoC and
deoR, and this strain was attenuated in chickens but not in
mice. The E. coli homologs of these genes encode a deoxyri-
bose phosphate aldolase and a repressor protein, respectively,
and are predicted to be part of the nucleoside catabolism
pathway. In E. coli, purine and pyrimidine nucleosides and
deoxynucleosides can be utilized in the nucleoside catabolic
pathway to extract pentose or deoxypentose for use as a carbon
and energy source. DeoC converts a deoxyribose intermediate
to glylceraldehyde-3-P and acetaldehyde, which can be utilized
in glycolysis and the TCA cycle, respectively. In E. coli, four
genes encoding the deoxynucleoside enzymes are located in
two adjacent operons, and the DeoR repressor protein, en-
coded elsewhere, binds to two DNA binding sites upstream of
the deoC, -A, -B, and -D genes, thereby generating a loop in the
DNA and preventing initiation of transcription (32). In P.
multocida, the gene arrangement is different, with only deoC
and deoR being adjacent to each other. Without a functional
deoxyribose aldolase enzyme, the mutant will be unable to
convert the deoxyribose intermediates to the final products in
the pathway. In a rich in vitro medium, this pathway may not be
essential for the mutant to grow normally, but in chickens, the
bacteria may need to utilize nucleosides as an alternative
source of carbon and energy. It is also possible that in the
mutant, the transposon insertion upstream of deoC and deoR
affects the transcriptional regulation of the deo genes, as the
DeoR repressor protein may no longer be synthesized.
Mutants with altered cell envelopes. Three genes predicted
to be involved in cell envelope biosynthesis were identified:
ponC, pm1294, and dcaA. The mutant AL389 had a transposon
insertion in ponC, a homologue of the E. coli gene pbpC, which
encodes the protein PBP1C that has a penicillin-binding do-
main and functions as a transglycosylase for murein polymer-
ization (45). Murein is required for the biosynthesis of the
murein sacculus, the scaffolding structure of the bacterial cell
wall. Mutants in the pbpC gene in E. coli are viable in vitro, but
the cross-linkage of the murein structure is different from that
of the wild type, with mainly nascent murein being used for the
biosynthesis of the sacculus instead of a combination of pre-
existing murein strands with newly synthesized ones (37, 45).
The P. multocida ponC mutant was also viable in vitro but
showed significant attenuation in chickens, perhaps indicating
that the changed structure of the murein sacculus affects the
integrity of the cell wall, making the mutant more susceptible
to osmotic stress in vivo.
Three mutants, namely, AL251, AL390, and AL391, were
identified with insertions in the gene pm1294. This gene is
predicted to encode a heptosyl transferase, as the amino acid
sequence displayed 58% identity to the heptosyltransferases II
and III from Haemophilus ducreyi. These H. ducreyi proteins
are glycosyltransferases responsible for the addition of heptose
to lipooligosaccharide (15). The three P. multocida mutants
had the transposon inserted at the same site, but in one,
AL390, the transposon was in the opposite orientation. Inter-
estingly, each mutant showed different levels of attenuation in
mice and chickens. Strain AL251 was significantly attenuated
in mice, whereas AL390 and AL391 were not. In chickens, all
three strains were attenuated, but AL251 and AL391 were
more so than AL390. Although the mutant AL251 was signif-
icantly attenuated in mice, with an average rCI value of 0.62, it
was more highly attenuated in chickens, with an average rCI of
less than 0.01. Interestingly, the strain AL391 had the same
insertion site and transposon orientation as AL251 and was
also highly attenuated in chickens, but in contrast, it showed no
attenuation in mice. Preliminary data on the virulence of
strains AL251 and AL391 indicate that they are both unable to
cause disease in chickens.
The mutant AL249 had an insertion in the gene annotated
as dcaA, whose protein’s amino acid sequence has a high de-
gree of identity with LptA and Lpt3 from Neisseria meningitidis
(12,28,31).InN.meningitidis, lpt-3and lptAencodephosphoetha-
nolamine transferases which are required for the addition of
phosphoethanolamine (PEtn) to specific sites within the inner
core of lipopolysaccharide (LPS) (12, 28). The inactivation of
lpt-3 in N. meningitidis resulted in bacteria that were lacking
PEtn on the LPS structure, and the mutants were less resistant
to bactericidal killing and in vitro opsonophagocytosis (28).
The dcaA gene has also been identified as being significantly
up-regulated in P. multocida during infections in chickens (8).
Preliminary structural information on the P. multocida LPS
purified from the wild-type VP161 indicates that a PEtn mol-
ecule is attached to the LPS (data not shown). Moreover,
based on the positions of PEtn in N. meningitidis (28) and
Haemophilus influenzae (38, 39), it is unlikely that the lack of
the PEtn in the mutant would have any significant effect on the
LPS structure that would result in major structural changes in
the outer membrane. Therefore, the attenuation observed in
the P. multocida mutant AL249 is likely to be a direct effect of
an altered LPS. Taken together, these data are consistent with
a more important role for LPS in the progression of fowl
cholera in chickens than in the progression of pasteurellosis in
mice. Currently, studies are being undertaken to analyze the
LPS composition of the mutant AL251 compared to wild-type
LPS.
Notably, in the previous STM study of a bovine pneumonia
isolate of P. multocida in a septicemic mouse model, another
LPS mutant was identified with an insertion in lgtC, encoding
a galactosyltransferase, the homologue of which in H. influen-
zae is responsible for the addition of galactose to the LPS
oligosaccharide (17, 21).
Mutants with insertions in genes encoding outer membrane
proteins and surface structures. Fimbriae have previously
been identified on the surface of P. multocida cells and genes
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encoding putative fimbriae, and fibrils are present in the P.
multocida genome (23, 31, 42, 44). However, it has not been
determined which of the fimbrial proteins are present within
the observed structures and what role, if any, they play in the
pathogenesis of disease. In this study, we identified one atten-
uated mutant, namely, AL250, with the transposon inserted
between the start codon and the putative promoter of the gene
pm0855. The deduced amino acid sequence of pm0855 has
43% identity with Flp1 from Actinobacillus actinomycetem-
comitans, and the gene is located at the start of a potential
operon containing 14 genes. This putative P. multocida operon
also contains other genes with similarities to those from the flp
operon of A. actinomycetemcomitans, including genes encoding
tight adherence proteins (Tad) that are thought to be involved
in the synthesis of long filamentous fimbriae (24). A second flp
homologue, flp2, was identified adjacent to flp1, but this puta-
tive gene has not been annotated in the published P. multocida
genome sequence (31). These two P. multocida genes contain
an Flp motif that has been predicted to be characteristic of a
new pilin gene subfamily (25).
In a previous STM study on P. multocida, a tadD mutant was
shown to be attenuated. The tadD gene is positioned down-
stream of the flp genes but potentially within the same operon
(17). To determine if the tadD gene was affected in the flp
mutant AL250, we measured the levels of RNA expressed
from selected genes within the putative operon. Quantitative
analysis of mRNA levels indicated that only the flp1 and, to a
lesser extent, flp2 mRNAs had reduced levels in the mutant,
while the mRNA expression levels of genes downstream of flp2
were identical to those of the wild type (data not shown). This
finding indicates that there may be a promoter located down-
stream of flp2. Given that the transposon was located between
the putative promoter and the start codon, it was surprising
that there was any mRNA expression from the flp1 gene in the
mutant.
In competitive growth assays, the flp mutant was consistently
attenuated in mice. However, in chickens, there was variation
in the level of attenuation between individual birds, with the flp
mutant being able to grow at levels similar to that of the wild
type in one of the four chickens tested. This may indicate real
variability in the growth of the strain in different birds or may
indicate that there is some instability of the mutant.
Finally, a mutant was identified with an insertion in pm1069,
the amino acid sequence of which has significant similarity to
the E. coli protein FadL and the P1 outer membrane protein
from H. influenzae. In E. coli, FadL has been identified as an
outer membrane porin required for the uptake of long-chain
fatty acids (5, 29). Mutants lacking FadL are unable to grow on
medium containing long-chain fatty acids as a sole carbon
source (35). A search of the PM70 genome sequence showed
that homologues of two other proteins required for the uptake
of long-chain fatty acids, namely, FadR and FadD, are also
present. The H. influenzae homologue P1 has been considered
a potential vaccine candidate for both type b and nontypeable
strains of H. influenzae, as both polyclonal and monoclonal
antibodies raised against P1 protect against bacteremia in the
infant rat model (19, 27). In H. influenzae type b, a P1 mutant
was shown to grow at the same rate as wild-type H. influenzae
in vitro and could still induce bacteremia in the infant rat
model (33). However, analysis of a P1 mutant in H. influenzae
biogroup aegyptius demonstrated that although both the wild
type and mutant grew at the same rate under anaerobic con-
ditions, the expression of P1 was up-regulated in the wild-type
strain (46). The P. multocida mutant AL386 was attenuated
only in chickens, suggesting that the uptake of long-chain fatty
acids as an energy source is required only during infections in
chickens and not during in vitro growth or during infections in
mice.
Concluding remarks. We have screened 420 P. multocida
STM mutants in both mice and chickens and identified 15
attenuated mutants and 13 disrupted genes or regions. Ten of
the insertions caused attenuation in chickens but not in mice,
indicating for the first time P. multocida virulence genes that
may be host specific. Five mutants were attenuated in both
hosts, and no mutants were identified that were attenuated in
mice but not in chickens.
Significantly, in this study, we did not identify any of the
genes identified in a previous STM study that used a bovine
pneumonia isolate of P. multocida in a mouse infection model.
However, several genes were identified that encoded proteins
involved in similar pathways (17). These differences are unsur-
prising, as the studies utilized different transposons, the P.
multocida strains were isolated from two very different diseases
(fowl cholera and bovine pneumonia), and each strain exhib-
ited different infection kinetics in the mouse model. Further-
more, it is likely that neither study approached saturation cov-
erage of the genome.
Mutant pools were introduced into the intraperitoneal cavity
of mice and via the breast muscle of chickens. While these
inoculation routes reliably cause disease in both animal mod-
els, these infection routes would not allow the detection of
bacteria with mutations in genes involved in the initial attach-
ment and colonization of mucosal surfaces. Previous studies
have indicated that birds can be infected via the respiratory
tract, and it has been demonstrated that P. multocida can
adhere to turkey air sac macrophages (40, 41, 43). Future
studies will aim to detect mutants unable to attach and colo-
nize by using intratracheal inoculation of the STM pools into
chickens.
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